no buyers why, page-13

TLopez i guess it also comes down to cost & while i'm not trying to put a price on life/health or specualting @ what the end cost will be but using Provenge's $93K you can turn that data to progression free survival for 100 days non-randomized CVAC & 44 days CVAC next to OSC. Is $93K good for those figures ? I guess that only comes down to the patients but it is still a signifcant sum for to consider. As stated though it works, the trend is heading in the right direction & it is only interim data, ability to widen that gap over time makes the story far more convincing.

I think it's very good news but I guess i can also see why some might not be impressed or where expecting things to show a far wider gap although that is always the story with interim data, it's following the right line but it still has time to show the full benefit.

Only my opinion